BridgeBio Pharma announced that it has commenced an underwritten public offering of $250M of shares of its common stock. All of the shares in the proposed offering are to be sold by BridgeBio. J.P. Morgan, Cantor Fitzgerald & Co. and Mizuho are acting as joint book-running managers for the proposed offering. Raymond James is acting as lead manager.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio price target raised to $46 from $42 at Citi
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- BridgeBio reports Q4 EPS (96c), consensus (91c)
- BridgeBio, Kyowa Kirin announces partnership
